The Nordic Compounder Playbook: How Lagercrantz Bought 90 Companies and Never Sold One
Release Date: 05/28/2026
The Discount Is the Wrong Question in Private Equity Secondaries
M&A Science
Secondary deals are often judged by a single metric: the discount. Richard Chow thinks that's the wrong place to start. After spending most of his career investing in and advising on secondaries, Richard has seen what happens when investors focus too heavily on price and miss what is actually driving the transaction. Richard and Kison walk through the decisions behind LP-led deals, continuation vehicles, private-market liquidity, and some of the assumptions buyers routinely get wrong. They also get into Richard's own investing mistakes, including a SpaceX opportunity he passed on, and what it...
info_outline
How to Finance Acquisitions Without Giving Up Equity
M&A Science
How do you keep buying companies without eventually losing control of the company you built? SS&C Technologies founder and CEO Bill Stone has spent four decades avoiding exactly that. Rather than treating each acquisition as an isolated transaction, SS&C built a system around protecting ownership, using debt when the economics make sense, paying it down quickly, and creating enough value after close to preserve capacity for the next deal. Bill walks through the decisions behind acquisitions including FMC, GlobeOp, and Blue Prism, his experience taking SS&C private with...
info_outline
Where AI Actually Helps and Fails in M&A Legal Work
M&A Science
AI can now draft, review, and benchmark deal documents in a fraction of the time it used to take, but knowing when to trust the output is a different skill entirely. Aaron Binstock, a partner at Cooley with nearly 20 years of transactional experience, has seen both sides of that tradeoff firsthand. Where does AI actually save time on a deal, and where does it create false confidence? What happened when a client's AI-generated tax step chart was built on the wrong assumption? How does reverse prompting produce a better first draft than a single one-shot prompt? And what's changing about how...
info_outline
The Back-Office Surprises Nobody Warned You About When Going Global
M&A Science
Due diligence covers deal terms, but it doesn't cover what happens once you're running payroll, benefits, and banking in a country you've never operated in before. A legal entity change can lock a company out of its own bank account overnight. Benefits plans get frozen in by local law. A language rollout can hit five systems on the same go-live day. And having handled one acquisition in a country doesn't guarantee the next one plays out the same way. Jennifer Lipschultz has led integration on more than 20 acquisitions across the Netherlands, Sweden, Germany, and India for ECI Software...
info_outline
How to Structure an Acquihire Deal in the AI Talent Race
M&A Science
AI talent deals are no longer small acquihires built around a simple price per engineer. Some now carry billion-dollar price tags, forcing buyers to rethink deal structure, diligence, tax exposure, and retention. Baker McKenzie’s M&A Partner Derek Liu has personally signed over $110 billion in transactions from both sides of the table. That mismatch, old tools built for a different kind of deal, is what's forcing corp dev and legal teams to rework their playbook, and it's the throughline of this conversation. What You'll Learn The real cost difference between a stock purchase, an asset...
info_outline
What Buyers Want from Bankers and Founders
M&A Science
Your standard teaser tells a buyer everything about your company and nothing about why you fit their strategy right now. When sellers expect the buyer to figure out that alignment, the deal dies on the desk. Andrew Morbitzer has led more than $2 billion in acquisitions at Intuit and GoDaddy, worked on the sell-side as an M&A advisor, and returned to the buy-side as VP of Corporate Development at Life360. What You'll Learn Why do corp dev teams default to no on inbound deals before the first conversation How banker incentives and buyer incentives point in opposite directions How to...
info_outline
220 Deals. One Playbook. How to Scale M&A Without Losing Control
M&A Science
If you scale the deal flow without the operating infrastructure to match it, things break fast. The playbook is a document nobody opens, closing weeks turn into fire drills, and the returns you modeled start to slip. Shawn Rodricks, Head of M&A - Independent Consultant, built the infrastructure before the volume hit. He closed 220 acquisitions across two organizations, 37 at Rexall in pharmacy and 183 at Amerivet Veterinary Partners, by wiring in the operating system from the start. What You'll Learn The five-part operating model behind 220 acquisitions How to hire for biz dev vs. corp...
info_outline
How to Build a Deal Model That Beats PE on Price
M&A Science
Buyers who mistake a high LOI bid for a winning strategy are easy prey for sellers who know the growth equity playbook. Jeremy Segal's position: precision at the LOI stage is a stronger differentiator than price. Jeremy Segal is EVP of Corporate Development at Progress (NASDAQ: PRGS), a publicly traded software company that has nearly doubled revenue through M&A, from under $400 million to nearly $1 billion. He has closed roughly 50 acquisitions across his career at Progress, LogMeIn, and Akamai. How do you build a cost-optimization model before LOI for lines you know you can execute?...
info_outline
The People You Lose in M&A: Key Talent Retention Before Close
M&A Science
The people who leave post-close are usually the ones the deal depended on. Which means the problem starts with how you read culture before LOI and whether financial incentives are the only retention tool you are building with. Haseeb Jawad heads corporate development at Commvault, running a lean team with full accountability from sourcing through integration. He has led two to three acquisitions per year across multiple companies, sat on both sides of a transaction, and serves as his own IMO lead. The signals that tell you a deal will lose people are visible from the first founder...
info_outline
How to Buy Companies That Aren't Profitable Yet
M&A Science
Venture-backed companies are priced at their future state, not their current revenue. When growth stalls and another fundraising round stops making sense, the gap between VC valuation and what a strategic buyer will pay becomes the hardest conversation in any deal process. Matt Arsenault, VP of Corporate Development & Strategic Alliances at Jamf, has run this play across hundreds of targets. His work starts before the deal does, with the founder relationship, the cap table, and a clear-eyed conversation about risk tolerance that most corp dev teams never have. What You'll Learn ...
info_outlineJörgen Wigh, CEO of Lagercrantz Group
Jörgen Wigh has been CEO of Lagercrantz Group (STO: LAGR-B) for over 20 years. In that time he completed 90+ acquisitions, built a portfolio of 85 niche B2B companies, and delivered 15 consecutive years of record earnings per share. No capital raises. No forced integration. No exits. The Nordic compounder model has quietly outperformed global markets for decades, and Lagercrantz is one of the longest-running, most disciplined examples of it in operation. In Part 1 of 2, Jörgen walks through the deal model behind that track record.
What You'll Learn
- How Lagercrantz finds companies that are not for sale, and why the first call almost never closes a deal
- How Jörgen pushes for exclusivity in weeks when most sellers are running a banker-led process
- The earnout structure Jörgen uses to keep founders motivated for three years after signing
- What he says when PE shows up at 11x and the seller is tempted to take the bigger check
- Why founders walk away from more money for legacy preservation, and the conversation that earns it
- How to close 8 to 12 deals a year without breaking pricing discipline
If you are holding pricing discipline against private equity and want to know whether your team would do the same, DealPilot, powered by M&A Science, runs the M&A Competency Assessment so you can benchmark deal judgment before the next term sheet.
____________________
This episode of M&A Science is presented by DealRoom.
DealRoom just automated Pipeline Management with AI so you can spend less time updating deals, and more time working them. Automatically push deal context from Outlook to DealRoom Pipeline and use AI to keep deal target data and tasks updated, so follow-ups never slip through the cracks. No manual logging. No stale pipeline data.
See for yourself at dealroom.net/pipelineai
____________________
Episode Chapters
[00:00] Introduction
[05:48] Jörgen's path: analyst, McKinsey, and the Bergman & Beving spinout
[07:00] Coming back as CEO in 2006 and rebuilding from scratch
[09:21] Buy and hold, forever: how the model actually works
[11:21] What makes a company worth buying (and what kills it)
[12:28] A real deal: helicopter deck safety systems
[13:52] Who sells to Lagercrantz, and why
[15:44] The only two things Lagercrantz adds: energy and structure
[20:17] Finding companies that are not for sale
[22:36] When the banker shows up: getting exclusivity early
[23:55] Holding the line at 4-8x EBITDA when PE bids 11x
[25:09] The legacy preservation pitch that wins without matching price
[33:38] Earnouts that keep founders motivated for three years
[36:17] Running 85 companies with 22 people at HQ
[36:46] The only three functions Lagercrantz centralizes
[37:57] The annual MD conference and the peer network behind it
[40:13] 8 to 12 deals a year, one a month